AATS Highlights include:
First Successful 3D Printed Trachea
A team of researchers from Icahn School of Medicine have combined 3D printing technology with human stem cells to create the first successful 3D-printed biologic tracheal graft in an animal model. Using a biocompatible polymer, researchers created a customized 3D-printed tracheal graft seeded with stem cells. The graft was then used to repair a defect in an animal. The Mount Sinai team continues to work toward creating a customized tracheal graft that could be used to repair complex airway defects in humans.
"We are very pleased with our early results and look forward to continuing our work in this area," said Faiz Bhora, MD, Chief of Thoracic Surgery at Mount Sinai Roosevelt and Mount Sinai St. Luke's, Associate Professor of Thoracic Surgery, Icahn School of Medicine. "The ability to produce a customized organ derived from biocompatible material or from a patient's own stem cells is the new frontier in biomedical engineering and may represent a future permanent treatment for patients with tracheal injuries." Other key members of the team include Robert Lebovics, MD, chief of otolaryngology at Mount Sinai St Luke's and Mount Sinai Roosevelt, Adnan Al-Ayoubi, MD, PhD, Sadiq Rehmani, MD, and Michael Barsky, BA, postdoctoral fellows in the thoracic surgery research lab.
Increased Mortality in Black Patients after Surgery for Esophageal Cancer
In a study led by Andrea Wolf, MD, Assistant Professor of Thoracic Surgery at the School of Medicine, African-American patients with esophageal cancer were found to have higher rates of mortality after surgery compared to their white counterparts. Researchers analyzed patient outcomes data from the Survival Epidemiology and End Results (SEER) database to determine the impact of surgery.
"We believe the disparity in survival may be attributed to the fact that blacks may not be staged adequately and lack access to more experienced, specialized thoracic surgeons," said Dr. Wolf. "Further studies are needed to access whether skilled surgeons may improve survival in these patients."
Is Surgical Resection Justified for Myasthenia Gravis?
In a study led by Andrew J. Kaufman, MD, Assistant Professor of Thoracic Surgery at the School of Medicine, patients receiving surgical treatment for Myasthenia Gravis, a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, achieved stable remission and improvement of symptoms after surgery. Researchers analyzed more than 1,000 patients who underwent a Thymectomy to remove the thymus, a specialized organ of the immune system. 19% of patients achieved complete stable remission; an additional 16% experienced improvement in symptoms requiring less medication after; and 58% were stable after surgery but developed progressive disease.
"Our analysis suggests surgery provides a significant chance of achieving complete and stable remission in many patients," said Andrew J. Kaufman, MD, Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai, "Surgery should be considered for the treatment of myasthenia gravis, especially in those with mild symptoms.
Provided by The Mount Sinai Hospital
This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.